Therapeutic Asset Ratings
329 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Osimertinib
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
CC
(46)
pd-1ab21-bcma car-t cell immunotherapy
Plasma Cell Myeloma
Daihong Liu
P2
CC
(46)
Talzenna
Plasma Cell Myeloma
American Society of Clinical Oncology
P2
CC
(46)
Tcr Transduced T-Cells
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
CC
(46)
Trastuzumab Deruxtecan
Multiple Myeloma
American Society of Clinical Oncology
P2
CC
(46)
Tucatinib
Plasma Cell Myeloma
Canadian Cancer Trials Group
P2
CC
(46)
Ulixertinib
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
CC
(46)
AZD1775
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
CC
(45)
Bosutinib
Plasma Cell Myeloma
Canadian Cancer Trials Group
P2
CC
(45)
Taselisib
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
CC
(45)
Abbv-453
Plasma Cell Myeloma
AbbVie
P1/2
CC
(45)
ct103a
Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
P1/2
CC
(45)
Fully Human Bcma Chimeric Antigen Receptor Autologous T Cell
Plasma Cell Myeloma
Nanjing IASO Biotechnology Co., Ltd.
P1/2
CC
(45)
Hdp-101
Plasma Cell Myeloma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
P1/2
CC
(45)
Immunoglobulin G1-kappa, anti-[Homo sapiens CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1)], humanized monoclonal antibody
Plasma Cell Myeloma
Keymed Biosciences Co.Ltd
P1/2
CC
(45)
Oricar-017
Plasma Cell Myeloma
OriCell Therapeutics Co., Ltd.
P1/2
CC
(45)
Futibatinib
Plasma Cell Myeloma
American Society of Clinical Oncology
P2
CC
(44)
Alnuctamab
Plasma Cell Myeloma
Celgene
P3
CC
(43)
Rimiducid
Plasma Cell Myeloma
Poseida Therapeutics, Inc.
P1/2
CC
(43)
cd19/bcma-targeted car-t cells
Plasma Cell Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P1
CC
(41)
Ruxolitinib [Jakafi]
Multiple Myeloma
Oncotherapeutics
P1
CC
(41)
Sotatercept
Plasma Cell Myeloma
Rebecca Silbermann
P2
CC
(40)
Maplirpacept
Plasma Cell Myeloma
Pfizer
P1
CC
(40)
Anti-Bcma/Fcrl5 Car T
Multiple Myeloma
Xuzhou Medical University
P1/2
CC
(40)
Anti-Fcrl5 Car-T
Plasma Cell Myeloma
Xuzhou Medical University
P1/2
CC
(40)
Showing 176 to 200 of 329 assets
Previous
Page 8 of 14
Next
